This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mithra Pharmaceuticals Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Christophe Marechal

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.4yrs
Proprietà del CEO	n/a
Durata media del management	4.3yrs
Durata media del Consiglio di amministrazione	2.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Christophe Marechal

7.4yrs

Mandato

Mr. Christophe Maréchal has been the Chief Financial Officer of Mithra Pharmaceuticals SA since February 23, 2017 and also serves as its Co-Chief Executive Officer since March 5, 2024. Mr. Maréchal serves...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christophe Marechal	Co-CEO & CFO	7.4yrs	Nessun dato	Nessun dato
Xavier Paoli	COO & Co-CEO	less than a year	Nessun dato	Nessun dato
Graham Dixon	Chief Scientific Officer	5yrs	Nessun dato	Nessun dato
Alex Sokolowski	Head of Investor Relations	no data	Nessun dato	Nessun dato
Fanny Rozenberg	Secretary of the Board & General Counsel	no data	Nessun dato	Nessun dato
Fanny Storms	Compliance Officer	no data	Nessun dato	Nessun dato
Frederique Depraetere	Communication Director	no data	Nessun dato	Nessun dato
Catherine Lejeune	HR Director	no data	Nessun dato	Nessun dato
Jean-Manuel Fontaine	Chief Business Officer	3.5yrs	Nessun dato	0.000040% € 6.0
Jean-Michel Foidart	President of the Scientific Advisory Board & Executive Director	no data	€7.12k	0.029% € 4.4k
Christophe Saillez	Head of Global Regulatory Affairs	no data	Nessun dato	Nessun dato
Maud Jost	Head of Program & Project Management	no data	Nessun dato	Nessun dato

4.3yrs

Durata media

Gestione esperta: Il team dirigenziale di 1TM è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jean-Michel Foidart	President of the Scientific Advisory Board & Executive Director	7.8yrs	€7.12k	0.029% € 4.4k
Jacques Platieau	Independent & Non-Executive Director	1.5yrs	€25.00k	Nessun dato
Valerie Gordenne	Non-Executive Director	2.6yrs	€20.00k	0.042% € 6.3k

2.6yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 1TM non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

This company listing is no longer active

Mithra Pharmaceuticals Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Mithra Pharmaceuticals SA Announces CEO Changes

Mithra Appoints Christian Homsy as Chairman

Mithra Approves Board Appointments

Mithra Pharmaceuticals SA, Annual General Meeting, May 25, 2023

Less than half of directors are independent

High number of new directors

Recent updates

Forecast to breakeven in 2026

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Mithra Pharmaceuticals SA Announces CEO Changes

Mithra Pharmaceuticals SA to Report First Half, 2024 Results on Sep 26, 2024

New major risk - Share price stability

Mithra Pharmaceuticals SA to Report Fiscal Year 2023 Results on Mar 08, 2024

No longer forecast to breakeven

No longer forecast to breakeven

New minor risk - Market cap size

First half 2023 earnings released

New major risk - Negative shareholders equity

Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023

Mithra Pharmaceuticals SA has completed a Follow-on Equity Offering in the amount of €20 million.

Mithra Pharmaceuticals SA announced that it has received €20 million in funding from Armistice Capital, LLC

Forecast breakeven date pushed back to 2025

New minor risk - Market cap size

Mithra Announces New Positive Preclinical Data from Csf-1R Inhibitor Program

Mithra Appoints Christian Homsy as Chairman

Mithra Approves Board Appointments

Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Mithra Pharmaceuticals SA to Report Fiscal Year 2022 Final Results on Apr 18, 2023

Mithra Pharmaceuticals SA, Annual General Meeting, May 25, 2023

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

First half 2022 earnings released: €0.69 loss per share (vs €1.28 loss in 1H 2021)

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mithra Pharmaceuticals SA announced that it expects to receive €23.500005 million in funding

High number of new directors

Full year 2021 earnings: Revenues miss analyst expectations

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

Forecast to breakeven in 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Full year 2020 earnings released: €2.25 loss per share (vs €0.70 loss in FY 2019)

Revenue misses expectations

Full year 2020 earnings released

Mithra and Searchlight Pharma Announces Nextstellis Approval in Canada

New 90-day high: €23.20

Mithra Pharmaceuticals SA to Report First Half, 2021 Results on Sep 24, 2021

Mithra Announces Executive Changes

Mithra Pharmaceuticals SA, Annual General Meeting, May 20, 2021

New 90-day high: €18.22

New 90-day low: €16.28

New 90-day low: €16.36

New 90-day low - €16.58

New 90-day low - €16.72

New 90-day low - €17.30

Mithra Pharmaceuticals SA has completed a Follow-on Equity Offering in the amount of €64.999988 million.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media